Boston gets $19m from Cordis for stent patent case
This article was originally published in Clinica
Executive Summary
Boston Scientific has won $19.5m in damages in a patent infringement case against its coronary stent rival, Johnson & Johnson's Cordis. The jury in the Delaware district court awarded the company $18.5m in lost profits and $1m in "reasonable royalties". Boston had initially sought $34m in damages (www.clinica.co.uk, 6 May 2011), which would have represented more than half of the $60m Cordis made in sales of the infringing stent, the 2.25mm Cypher. The profit made from this stent is around $14m. Boston had filed the suit against Cordis in December 2009; in April, Cordis was found guilty of infringing Boston's Jang patent, and it was later determined that the infringement was wilful.